Earnings Call Summary | Bio-Path Holdings(BPTH.US) Q1 2024 Earnings Conference
Earnings Call Summary | Bio-Path Holdings(BPTH.US) Q1 2024 Earnings Conference
The following is a summary of the Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript:
以下是Bio-Path Holdings Inc.（BPTH）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Bio-Path Holdings reported a net loss of $3.2 million or $4.88 per share for Q1 2024, which is an improvement from a net loss of $5.3 million or $13.25 per share for Q1 2023.
The company's cash balance as of March 31, 2024, was $0.2 million.
Research and development expenses decreased to $2.3 million, while general and administrative expenses mildly increased to $1.4 million.
After Q1, the company secured additional funding of $3.5 million through an at-the-market offering agreement and registered direct offering.
Bio-Path Holdings報告稱，2024年第一季度淨虧損320萬美元，合每股虧損4.88美元，較2023年第一季度的淨虧損530萬美元或每股虧損13.25美元有所改善。
截至2024年3月31日，該公司的現金餘額爲20萬美元。
研發費用降至230萬美元，而一般和管理費用略有增加至140萬美元。
在第一季度之後，該公司通過市場發行協議和註冊直接發行獲得了350萬澳元的額外融資。
Business Progress:
業務進展：
Bio-Path made significant advancements by receiving newly issued patents in Mexico, Australia, and Japan.
It achieved clinical trial progress with positive interim results for acute myeloid leukemia treatment with its lead product candidate, Prexigebersen.
The company plans to pursue FDA expedited programs for Fast Track designation for Prexigebersen AML treatment.
Progress was noted in the BP1002 program, targeting the Bcl-2 protein and showing encouraging results in dose escalation studies.
The Phase 1/1b clinical trial for BP1001-A for solid tumor types was launched, and progress was also made with the BP1003 program targeting the STAT3 protein.
Processes are underway to submit an investigational new drug (IND) application to the FDA for BP1003.
Bio-Path 在墨西哥、澳大利亞和日本獲得了新頒發的專利，取得了重大進展。
它通過其主要候選產品Prexigebersen取得了臨床試驗進展，在急性髓系白血病治療方面取得了積極的中期結果。
該公司計劃推行美國食品藥品管理局的加急計劃，爲Prexigebersen反洗錢治療指定快速通道。
BP1002 計劃取得了進展，靶向 Bcl-2 蛋白，劑量遞增研究顯示出令人鼓舞的結果。
針對實體瘤類型的 BP1001-A 的 1/1b 期臨床試驗已經啓動，針對 STAT3 蛋白的 BP1003 計劃也取得了進展。
向美國食品藥品管理局提交 BP1003 研究性新藥（IND）申請的程序正在進行中。
More details: Bio-Path Holdings IR
更多詳情： 百路控股投資者關係
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。